Insulin glargine is produced by recombinant DNA technology ... which shifts the isoelectric point from a pH of 5.4 to 6.7. It results in an insulin molecule less soluble at the injection site ...

Objective—Insulin glargine (Lantus) is an extended-action insulin analog with greater stability and duration of action than regular human insulin. The long duration of action and decreased ...

The Europe-wide approval is the first ever insulin treatment licensed through the European Medicines Agency's biosimilar pathway, and the fourth diabetes product approved in the EU from the Lilly ...